Comparative Pharmacology
Head-to-head clinical analysis: SESQUIENT versus SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SESQUIENT versus SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE.
SESQUIENT vs SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
Sodium ferric gluconate complex in sucrose provides elemental iron for hemoglobin synthesis and replenishes iron stores in iron-deficient states. The iron complex is taken up by the reticuloendothelial system, where iron is released and bound to transferrin for erythropoiesis.
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
125 mg elemental iron (10 mL) intravenously over at least 10 minutes, given at sequential dialysis sessions to a cumulative total dose of 1000 mg elemental iron.
None Documented
None Documented
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Terminal elimination half-life is approximately 6 hours for the iron-sucrose complex; clinical context: indicates redistribution and utilization for erythropoiesis, with full hemoglobin correction over weeks.
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Primarily excreted via feces (93%) as non-absorbed iron; renal elimination of absorbed iron is minimal (<1%).
Category C
Category C
Iron Supplement
Iron Supplement